Clinical Predictors of Mortality and Heart Failure Hospitalization in Patients With Severe Tricuspid Regurgitation.
Heart failure hospitalization
Mortality
Outcomes
Tricuspid regurgitation
Journal
Structural heart : the journal of the Heart Team
ISSN: 2474-8714
Titre abrégé: Struct Heart
Pays: United States
ID NLM: 101743256
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
22
09
2022
revised:
04
11
2022
accepted:
07
11
2022
medline:
5
6
2023
pubmed:
5
6
2023
entrez:
5
6
2023
Statut:
epublish
Résumé
There is an incomplete understanding of the predictors of morbidity and mortality in patients with severe tricuspid regurgitation (TR). This study sought to identify key risk factors for all-cause mortality and heart failure (HF) hospitalization among patients with severe TR. Patients with severe TR were identified from 2 centers, Oregon Health & Science University and Abrazo Health, from January 01, 2016 to December 31, 2018. Patients with any concomitant severe valvular diseases or prior valvular intervention were excluded. Multivariable regression was utilized to identify demographic, clinical, and echocardiographic variables independently associated with all-cause mortality or HF hospitalization. 435 patients with severe TR were followed for a median of 2.8 years. The mean age of the population was 66.9 ± 18.5 years and 58% were female. All-cause mortality was identified in 20.5% of the population. Of the cohort, 35.4% of patients were hospitalized for HF. Isolated tricuspid valve intervention was performed in 2.5% of patients. Independent predictors of all-cause mortality included history of solid tumor (odds ratio [OR] 6.6, 95% confidence interval [CI] 2.1-19.1, Severe untreated TR is associated with high mortality and frequent HF hospitalizations. Understanding predictors of these outcomes is important to identify patients who may benefit from early tricuspid valve intervention to help improve outcomes in this patient population.
Sections du résumé
Background
UNASSIGNED
There is an incomplete understanding of the predictors of morbidity and mortality in patients with severe tricuspid regurgitation (TR). This study sought to identify key risk factors for all-cause mortality and heart failure (HF) hospitalization among patients with severe TR.
Methods
UNASSIGNED
Patients with severe TR were identified from 2 centers, Oregon Health & Science University and Abrazo Health, from January 01, 2016 to December 31, 2018. Patients with any concomitant severe valvular diseases or prior valvular intervention were excluded. Multivariable regression was utilized to identify demographic, clinical, and echocardiographic variables independently associated with all-cause mortality or HF hospitalization.
Results
UNASSIGNED
435 patients with severe TR were followed for a median of 2.8 years. The mean age of the population was 66.9 ± 18.5 years and 58% were female. All-cause mortality was identified in 20.5% of the population. Of the cohort, 35.4% of patients were hospitalized for HF. Isolated tricuspid valve intervention was performed in 2.5% of patients. Independent predictors of all-cause mortality included history of solid tumor (odds ratio [OR] 6.6, 95% confidence interval [CI] 2.1-19.1,
Conclusions
UNASSIGNED
Severe untreated TR is associated with high mortality and frequent HF hospitalizations. Understanding predictors of these outcomes is important to identify patients who may benefit from early tricuspid valve intervention to help improve outcomes in this patient population.
Identifiants
pubmed: 37275596
doi: 10.1016/j.shj.2022.100130
pii: S2474-8706(22)01936-4
pmc: PMC10236773
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100130Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
Dr. Zahr reports research grants from Edwards Lifesciences, Medtronic and Siemens. Dr. Zahr is also an Associate Editor of Structural Heart Journal. Dr. Golwala reports serves as an advisory consultant for Medtronic. Dr. Song reports serves as a consultant for Medtronic and Edwards Lifesciences. Dr. Chadderdon reports is an educational consultant for Medtronic and Edwards Lifesciences. Dr. Byrne reports is an educational consultant and proctor for Medtronic and is a proctor for Abbott Vascular. The other authors had no conflicts to declare.
Références
JACC Cardiovasc Imaging. 2019 Mar;12(3):433-442
pubmed: 30121261
J Am Coll Cardiol. 2004 Feb 4;43(3):405-9
pubmed: 15013122
J Am Soc Echocardiogr. 2003 Jul;16(7):777-802
pubmed: 12835667
J Am Coll Cardiol. 2017 Apr 11;69(14):1795-1806
pubmed: 28385308
Circ J. 2010 Feb;74(2):375-80
pubmed: 20009355
Am J Cardiol. 1999 Mar 15;83(6):897-902
pubmed: 10190406
Circ Cardiovasc Imaging. 2015 Jun;8(6):
pubmed: 26063743
Mayo Clin Proc. 2019 Oct;94(10):2032-2039
pubmed: 31279540
JACC Heart Fail. 2019 Feb;7(2):87-97
pubmed: 30553904
Heart. 2018 May;104(10):798-806
pubmed: 29229649
Circ Heart Fail. 2014 Nov;7(6):911-7
pubmed: 25190672
J Am Coll Cardiol. 2021 Jan 26;77(3):229-239
pubmed: 33478646
JACC Cardiovasc Interv. 2017 Oct 9;10(19):1994-2003
pubmed: 28780036
JACC Cardiovasc Interv. 2021 Jul 26;14(14):1538-1548
pubmed: 34020928
JACC Cardiovasc Interv. 2017 Aug 28;10(16):e147-e149
pubmed: 28780038
Circulation. 2019 Jul 16;140(3):196-206
pubmed: 31117814
JACC Cardiovasc Interv. 2021 Mar 8;14(5):501-511
pubmed: 33582084
Circulation. 2016 Mar 15;133(11):1104-14
pubmed: 26976915
Eur Heart J. 2013 Jul;34(25):1875-85
pubmed: 23303656
J Am Coll Cardiol. 2014 Jun 10;63(22):e57-185
pubmed: 24603191
Open Heart. 2019 Oct 3;6(2):e001104
pubmed: 31673390
JACC Cardiovasc Interv. 2022 Mar 14;15(5):471-480
pubmed: 35272771
JACC Cardiovasc Imaging. 2014 Dec;7(12):1185-94
pubmed: 25440592
Eur Heart J. 2013 Mar;34(11):844-52
pubmed: 23335604
Ann Thorac Surg. 2019 Jun;107(6):1713-1719
pubmed: 30639362
Heart. 2019 Aug;105(16):1244-1250
pubmed: 31092546
Am Heart J. 2002 Sep;144(3):524-9
pubmed: 12228791
Circulation. 2017 Jun 20;135(25):e1159-e1195
pubmed: 28298458